Skip to main content
. 2022 Jan 20;5(1):e2144369. doi: 10.1001/jamanetworkopen.2021.44369

Table 2. Availability of Medication for the Treatment of Opioid Use Disorder Among Pregnant Individuals in US Jails.

MOUD availability Jails, No./total No. (%)
During pregnancy
MOUD availablea 504/836 (60.3)
Continuation only 237/504 (47.0)
Initiation and continuation 267/504 (53.0)
Methadone available 385/504 (76.4)
Continuation only 247/385 (64.2)
Initiation and continuation 137/385 (35.6)
Buprenorphine available 381/504 (75.6)
Continuation only 171/381 (44.9)
Initiation and continuation 210/381 (55.1)
Methadone only available 123/504 (24.4)
Continuation only 84/123 (68.3)
Initiation and continuation 39/123 (31.7)
Buprenorphine only available 119/504 (23.6)
Continuation only 46/119 (38.7)
Initiation and continuation 73/119 (61.3)
Both methadone and buprenorphine available 262/504 (52.0)
Continuation only 107/262 (40.8)
Initiation and continuation 152/262 (58.0)
Withdrawal only (no MOUD available)b 190/577 (32.9)
Withdrawal and MOUD availablec 387/577 (67.1)
During postpartum period
MOUD available for continuationd 120/504 (23.8)
No MOUD continuation 274/504 (54.4)
Discontinuation with tapering 165/274 (60.2)
Abrupt discontinuation 61/274 (22.3)
Conditional discontinuatione 47/274 (17.2)
Did not report 110/504 (21.8)

Abbreviation: MOUD, medication for opioid use disorder.

a

Data do not include jails for which the provision of MOUD was uncertain.

b

There was a higher likelihood of doing withdrawal only among paper responses than among online responses (126 vs. 64; P = .01).

c

There was a higher likelihood of doing withdrawal and MOUD among paper responses than among online responses (267 vs. 120; P = .03).

d

Among jails providing MOUD during pregnancy.

e

Some respondents stated that they did not routinely continue providing MOUD after pregnancy but would consider allowing it depending on the remaining time in an individual’s jail sentence or whether an individual was expressing breast milk.